Open AccessSuccessful thrombolysis for acute ischaemic stroke after reversal of dabigatran etexilate with idarucizumab
Author(s) -
Chee Hoou Loh,
Geoffrey Herkes
Publication year - 2019
Publication title -
bmj case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.231
H-Index - 26
ISSN - 1757-790X
DOI - 10.1136/bcr-2018-229128
Subject(s) - dabigatran , medicine , thrombolysis , idarucizumab , ischaemic stroke , atrial fibrillation , stroke (engine) , direct thrombin inhibitor , intensive care medicine , anesthesia , cardiology , warfarin , myocardial infarction , mechanical engineering , engineering
We report the experience of reversing dabigatran prior to administering systemic thrombolysis for acute ischaemic cerebellar stroke, which was well tolerated with no haemorrhagic complications after thrombolysis. Given the increasingly common use of dabigatran for atrial fibrillation, the use of idarucizumab to reverse of dabigatran is a novel treatment that should be considered as an important adjunct to facilitate thrombolysis for ischaemic strokes and minimise haemorrhagic complications.